Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.42 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 18/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19687122 | 0.95 | KCNN2 (0.42) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19687421 | 0.92 | ADORA2A (0.46) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19687424 | 0.91 | ADORA2A (0.47) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19686525 | 0.89 | ADORA2A (0.47) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL31127310 | 0.89 | ADORA2A (0.47) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19686526 | 0.89 | ADORA2A (0.47) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19686909 | 0.89 | ADORA2A (0.47) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19686946 | 0.85 | KCNN2 (0.48) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19687077 | 0.84 | KCNN2 (0.47) | KCNN2KCNN3ADORA2AADORA1CYP1A2 | |
| SCHEMBL19687074 | 0.83 | KCNN2 (0.46) | KCNN2KCNN3ADORA2AADORA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | KCNN2 5/4885KCNN3 11/4885ADORA2A 1711/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | KCNN2 5/4885KCNN3 11/4885ADORA2A 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.